LJ001|cas:851305-26-5|西域试剂

LJ001,98.09%

产品编号：Bellancom-16957| CAS NO：851305-26-5| 分子式：C₁₇H₁₃NO₂S₂| 分子量：327.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16957	￥2000.00	杭州北京（现货）
Bellancom-16957	￥3200.00	杭州北京（现货）
Bellancom-16957	￥6500.00	杭州北京（现货）
Bellancom-16957	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LJ001

产品介绍

LJ001 是一种广谱的具有口服活性的抗病毒活性分子。LJ001 通过与病毒膜结合发挥抗病毒活性。LJ001 抑制 TGEV 和 PDCoV 感染。LJ001 降低 TGEV N 和 PDCoV N 蛋白的表达。

生物活性

LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression.

体外研究

LJ001 (0.782- 200 μM; 24 h) 没有显着的细胞毒性，对 ST 细胞的 CC₅₀ 值为 146.4 μM。
LJ001 (12.5 µM; 12, 24 h) 抑制传染性胃肠炎病毒 (TGEV) 和猪三角洲冠状病毒 (PDCoV) 感染。
LJ001 (12.5 µM; 1, 6,12, 24 h) 降低 ST 细胞中的 TGEV 和 PDCoV 基因 mRNA 表达。
LJ001 可以抑制一些包膜病毒的进入和传播，包括人类免疫缺陷病毒(HIV)、丙型肝炎病毒(HCV)、流感病毒、埃博拉病毒、沙粒病毒和痘病毒。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	ST cells
Concentration:	0.782, 1.563, 3.125, 6.25, 12.5, 25, 50, 100, 200 μM
Incubation Time:	24 h
Result:	Showed slight cytotoxicity with a CC₅₀ value of 146.4 μM.

Western Blot Analysis

Cell Line:	ST cells
Concentration:	12.5 µM
Incubation Time:	12, 24 h
Result:	Decreased the expression of TGEV N protein and PDCoV N-protein at 24 h and markedly reduced TCID₅₀ titers at 12 and 24 h.

RT-PCR

Cell Line:	ST cells
Concentration:	12.5 µM
Incubation Time:	1, 6, 12, 24 h
Result:	Inhibited TGEV and PDCoV gene mRNA expression in a time-dependent manner.

体内研究
(In Vivo)

LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) 在小鼠中未显示出毒性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	20, 50 mg/kg
Administration:	Oral gavage or i.p.; daily for 7 days
Result:	Revealed no abnormalities except a slight elevation in serum cholesterol levels in the treated vs. vehicle control group.

体内研究

LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) 在小鼠中未显示出毒性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	20, 50 mg/kg
Administration:	Oral gavage or i.p.; daily for 7 days
Result:	Revealed no abnormalities except a slight elevation in serum cholesterol levels in the treated vs. vehicle control group.

体内研究

LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) 在小鼠中未显示出毒性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	20, 50 mg/kg
Administration:	Oral gavage or i.p.; daily for 7 days
Result:	Revealed no abnormalities except a slight elevation in serum cholesterol levels in the treated vs. vehicle control group.